(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue of $22.4 million for the fourth quarter.
The net product revenue was is in line with its prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth quarter of 2024, stated CEO Ramy Mahmoud.
For prescriptions, the company estimates an approximately 20% sequential growth rate in the fourth quarter 2024.
The company said it continues to focus on commercial execution and continued growth in the year ahead.
The company expects to report fourth-quarter results in March.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
